SlideShare a Scribd company logo
Medical
Marijuana
Corporate Presentation
November 2014
This presentation does not constitute an offer to sell or solicitation of
an offer to buy any of the securities described herein. The sole
purpose of this presentation, in paper or electronic form, is strictly for
information.
Forward Looking Statement
This presentation contains forward-looking statements and "forward-looking information" within the meaning of applicable Canadian securities
legislation, including statements relating to business trends, Windfire Capital Corp. expectations with respect to the demand for its services and
products, the Windfire Capital Corp.’s intention with respect to its business strategy and competition and changes in the competitive landscape. All
statements, other than statements of historical fact, included herein may be forward-looking information. Generally, forward-looking information may
be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the
use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. This forward
looking information reflects Windfire Capital Corp.’s current beliefs and is based on information currently available to Windfire Capital Corp. and on
assumptions Windfire Capital Corp. believes are reasonable. These assumptions include, but are not limited to, the size and/or economics of the
market, plans and intentions to increase market share, expand geographically and/or further develop product capabilities, the results of strategic
initiatives, and the impact of competition.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity,
performance or achievements of Windfire Capital Corp. to be materially different from those expressed or implied by such forward-looking
information. Such risks and other factors may include, but are not limited to: the stage of development of Windfire Capital Corp. and its projects,
general business, economic, competitive, political and social uncertainties; changes in legislation, the corporate governance environment and regulatory
reporting requirements for Windfire Capital Corp. clients, product capability and acceptance, actions from competitors, Windfire Capital Corp.’s ability
to generate sufficient cash flow from operations to meet its current and future obligations, and Windfire Capital Corp.’s ability to access external sources
of financing if required, and lack of qualified, skilled about and the loss of key individuals. Although Windfire Capital Corp. has attempted to identify
important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors
that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking
information. Windfire Capital Corp. does not undertake to update any forward-looking information, except in accordance with applicable securities
laws. Also, please review the Ontario and USA disclaimer at end of the presentation.
© 2014 Windfire Capital Corp. All rights reserved. Copyright. All materials displayed or otherwise accessible through this Presentation (collectively,
"Content") are protected by copyright law, and are owned by Windfire Capital Corp. Corp. (“WIF”) and its licensors, or the party accredited as the
provider of the Content. Except as granted in the limited license herein, any use of the Content, including modification, transmission, presentation,
distribution, republication, or other exploitation of the Presentation or of its Content, whether in whole or in part, is prohibited without the express
prior written consent of WIF.
2www.windfirecapital.com
About Windfire Capital Corp.
• Windfire Capital Corp. (“Windfire”) is publicly traded company on the TSX
Venture Exchange, TSX.V ("WIF"), and the company is led by an experienced
management team comprised of public market professionals and skilled
operational people from the Medical Marijuana industry.
• Windfire has received conditional approval to list on Canadian Securities
Exchange (CSE) as a Life Science issuer and subsequently delist from the TSX.V.
• Windfire has executed definitive agreement with Rosebud Productions Inc.,
(“Rosebud”) located in Richmond, British Columbia. Rosebud has submitted an
application to Health Canada to become a LP of Medical Marijuana under the
new MMPR.
• Windfire sees this agreement with Rosebud as being the first step in becoming
a multi licensed producer. On that basis, Windfire continues to search for other
related opportunities in the Medical Marijuana industry and looks forward to
becoming a leading producer of the highest quality Medical Marijuana.
3www.windfirecapital.com
About Rosebud Productions Inc.
 Rosebud, a private company incorporated under the laws of British
Columbia.
 Rosebud has an application pending with Health Canada for the newly
implemented MMPR license. Once the application is approved Rosebud
expects to be producing Medical Marijuana by next spring.
 The Rosebud team consists of seasoned industry personnel with
experience in all aspects of Medical Marijuana production including
cultivation, facility design and construction.
 Incoming Windfire board member Gary Quo Vadis and partner Jesse
McConnell are the founders and controlling shareholders of Rosebud.
 Gary Quo Vadis currently holds a licence under the MMAR regulations.
www.windfirecapital.com 4
The Opportunity
Government of Canada is both exiting the production business and
eliminating the practice of allowing nearly 30,000 home growers.
Marijuana* for Medical Purposes Regulations legislation from Health Canada has
defined a commercial supply chain.
 The Canadian Association of Chiefs of Police has been working closely with
Health Canada to ensure these regulations address public safety considerations.
 Medical marijuana grew from under 500 prescriptions in 2002 to more than
28,000 in 2012 and is expected to reach 40,000 in 2014.
 A recent Health Canada survey indicates ~2.0% of Canadians believe they are
eligible to use medicinal marijuana, compared to 0.08% of the population
currently benefiting from use.
 2.0% participation is consistent with other jurisdictions where access
requirements have been relaxed (i.e. Colorado).
5www.windfirecapital.com
 In June 2013, the Government of Canada published the new Marijuana for
Medical Purposes Regulations (“MMPR”) replacing the existing marijuana
Medical Access Program (“MMAR”) that was introduced in 2001
 In 2001, there were 500 authorized users of medicinal marijuana in
Canada, today there are 35,000+
MMPR Regulations
MMPR (2013)
 Required specialist consultation and prescription including 20-page application form
 Licensed commercial producers
 Regulated quality control standards
 Physical security regulations and enforcement
 Detailed record keeping and audit from seed to end product
 Ability to purchase directly from Health Canada
www.windfirecapital.com 6
Investment Highlights
 Proven Management
 Experienced operational
cultivation team
 Application submitted to
Health Canada
 Superior Growth Strategy
 Strong growth predicted
industry wide.
www.windfirecapital.com 7
How the MMPR Process Works
 Patients obtain a prescription from a medical doctor
for medicinal marijuana with a Health Canada
prescription number.
 To purchase the medicinal marijuana, patients must
provide their original prescription to a commercial
producer.
 Authorized patients then select a commercial
producer to fill and ship their prescription.
 No advertising is permitted under new MMPR
regulations. Patients will select a vendor from
Health Canada’s website, medical practitioner
or brand awareness.
 Prescription are shipped directly from the
producer’s facility to the patient using a bonded
courier.
www.windfirecapital.com 8
The Market
 The present market is estimated at 37,000 patients.
 According to Health Canada, the current licenses translate to about 3.5
million plants.
 If each of those 3.5 million plants contributed an average of 56 grams that
equates to $1.4 billion at an average price of $7.15. This number does not
include the recreational user who buys on the black market.
 Health Canada anticipates by 2024 there will be more than 450,000 people
using marijuana for medical reasons, creating billions in annual sales.
 A majority of people in Canada believe marijuana should be readily available
for those who want to use it.
 A recent Angus Reid Public Opinion poll has found:
– In the online survey of representative national samples, a majority of Canadians (57%) and
Americans (54%) support the legalization of marijuana.
– Most respondents in each Canadian region back the legalization of cannabis, including 64
per cent of Atlantic Canadians and 60 per cent of British Columbians.
www.windfirecapital.com 9
Review of Potential Market
 The number of prescription users in
Canada is expected to grow tenfold
over the next ten years.
 Health Canada has issued 23 licenses
to date.
 Estimates indicate 37,000 patients
will use an average of 2 grams per
day equating to 27,010 kg and will
grow to 270,100 kg over the next ten
years.
 Recently released Liberal Party of
Canada research indicates 3 million
users in Canada equating to a six
billion dollar market place.
www.windfirecapital.com 10
Financial Projections
11www.windfirecapital.com
2015 2016 2017 2018 2019
Revenue $2,939,650 $7,055,160 $10,317,150 $16,126,080 $26,210,328
Net Income $917,522 $3,653,911 $5,760,732 $9,734,278 $16,767,606
New Equity Investment $3,500,000 $1,500,000 $1,500,00
Cash From Operations $995,424 $3,848,406 $5,995,199 $10,077,907 $17,096,338
Total Assets $4,897,230 $10,160,618 $17,508,278 $27,441,095 $44,382,900
Total Equity $4,850,932 $10,004,843 $17,265,575 $26,999,852 $43,767,458
Earnings per Share (assume 45.5M) $0.02 $0.08 $0.13 $0.21 $0.37
Return on Equity 18.9% 36.5% 33.4% 36.1% 38.3%
Return on Revenue 31.2% 51.8% 55.8% 60.4% 64.0%
Financials Projections Summary – Year Ending December 31, 2015-2019
Revenue & Income Growth 5YR
www.windfirecapital.com 12
2015 2016 2017 2018 2019
Revenue $2,939,650 $7,055,160 $10,317,150 $16,126,080 $26,210,328
Net Income $917,522 $3,653,911 $5,760,732 $9,734,278 $16,767,606
Revenue & Income Growth
Review of Competition
 Industry experts expect high margins as prices initially range from
$5-$20 per gram while production costs are expected to be $1-$2
per gram.
 Operating expenses will include capital expenditures, production,
sales & marketing, and security.
 Successful companies will be those that can demonstrate the
ability to manufacture, deliver, and scale quickly.
 Producers will have to have experienced cultivation and
horticulture specialists, careful quality control and security
measures, and thorough record keeping procedures to satisfy
Health Canada
13www.windfirecapital.com
The Acquisition – Rosebud
 Pursuant to the terms of the share exchange agreement signed July 15,
2014, the total purchase price, $5 million for Rosebud.
 Windfire will make an advance payment of $250,000 dollars to
Rosebud on exchange approval.
 A 2nd cash payment of $750,000 will be made to Rosebud on
conformation that Health Canada has issued a permit to build the
cultivation / production facility.
 A 3rd cash payment of $1,000,000 dollars will be made to Rosebud on
Health Canada granting the MMPR license to operate.
 A final payment of $3,000,000 dollars in shares will be paid in two
tranches over two years based on performance criteria.
www.windfirecapital.com 14
Technical Team
Cindy Chow, B.Sc. in Food, Nutrition, and Health – Quality Assurance / Safety Manager
 Miss Chow has over 8 years’ experience in the food industry specializing in Quality
Assurance, Regulatory Affairs, HPLC, Research and Development and Internal Auditing
 Solid understanding of GFSI recognized schemes with internal audit experience against
BRC and FSSC 22000 standards and ISO 9001:2008 standards
 Extensive knowledge of CFIA/FDA regulations and labelling of various RTE products
 Experienced in HACCP, GMP, GLP, and Pre-requisite Programs
 Outstanding trouble-shooting, problem solving, and time management skills with the
ability to work effectively in a team based environment or independently
Dean Laidlow – Chief Technical Advisor
 Mr. Laidlow has consulted both domestically and internationally in the Medical
Marijuana Industry for many years during which time he has developed a vast pool of
contacts.
 Dean has supervised numerous medical marijuana facilities on a day to day basis
resulting in an intimate understanding of all operational aspects of commercial medical
marijuana growing facilities. Additionally, he has designed and been instrumental in the
construction phase of numerous growing facilities.
www.windfirecapital.com 15
Technical Team Cont’d.
Victor Lam – Head Grower
 Mr. Lam as head grower has managed all activities related to growing with
Rosebud.
 Mr. Lam has knowledge of large scale commercial plant cultivation including
nutrient requirements, mediums, light requirements, temperature control, and air
flow.
 Has experience managing a large-scale warehouse with 100 thousand watt grow
lights.
 Manages plant scheduling and organization to precisely project all garden needs
on a daily, weekly, and monthly basis to keep garden green and expenses low.
 Responsible for Cataloging and analyzing each individual strain from clone to
flower to harvesting.
 Working knowledge in container systems with soil and hydro as well as
understanding temperature and humidity manipulation.
 Develop and/or maintain grow warehouse protocols and nutrient regiment.
 Oversee work force of 10 employees.
www.windfirecapital.com 16
Facility Build Out
 The cost of the facility is
estimated to be $500,000. This
cost includes, upgrading the fire
suppression system, adding
4,200 sq. ft. of mezzanine area,
purchasing panel wall system,
upgrading the electrical systems
and installing a state of the art
security system including a
vault.
www.windfirecapital.com
Projects ($000) Costs
Vault $50
Mezzanine build out $125
Wall paneling system $90
Fire suppression system $40
Security system $30
Inventory management & POS system $15
Lights, Co2 system, ventilation $150
Total Capital Expenditure $500
17
Management & Board
Clive Massey – President & Chief Executive Officer and Director
 Mr. Massey was previously the President and Chief Executive Officer of Universal
Uranium Inc. from 2005 to 2007. From 2005 to 2007, Mr. Massey worked for
several successful public companies including Lumina Copper Corp., which was
purchased by Teck Cominco Ltd. in 2008. Mr. Massey has held management or
investor relations positions with Inca Pacific, Greystar Resources, Marafill Mines,
Everett Resources Ltd. and The North Air Group of Companies.
Brian Morrison, BComm – Chief Financial Officer and Director
 Mr. Morrison received a bachelor of commerce degree from the University of
Northern British Columbia in 2004, and completed the Canadian securities course
in 2006. From January, 2005, to May, 2008, Mr. Morrison was an account manager
with Computershare Investor Services Inc., an international full-service financial
services, corporate trust and stock transfer company, and since June, 2008, he has
been a self-employed consultant working in the area of public company
administration. Mr. Morrison currently serves and has previously served as a
director or as chief financial officer of various publicly traded issuers.
18www.windfirecapital.com
Management & Board Cont’d.
Robert C. Harrison – Director
 Mr. Harrison has spent 35 years as an executive in branding, marketing and
General Management and after having attained the position of Senior Vice
President and General Manager of William Neilson Ltd. Mr. Harrison went on to
build several other very successful brands and was responsible for acquiring the
licenses and launching both Haagen Dazs and Ben & Jerry's Ice Cream in Canada.
Mr. Harrison has consulted for many Fortune 500 companies including Heinz,
Nabisco, Nestle and Slim Fast. He has an extensive corporate background in
product branding, licensing, manufacturing and the food processing industry. Mr.
Harrison is currently President of Global Garden Group of Vancouver, B.C., which is
a dairy-free natural food beverage. He was also responsible for engaging and
securing the license in Canada for Cadbury and Weight Watchers and in raising in
excess of $30 million for plant construction and operational deployment. His
extensive back ground includes, numerous debt and equity financings, reverse
take overs and the creation of a business strategy that has resulted in business
growth in excess of 50% year over year.
19www.windfirecapital.com
Management & Board Cont’d.
Gary Quo Vadis, BBA – Director
 Mr. Quo Vadis has a diverse business background that includes start-up businesses
and or buying existing businesses over the last 25 years. Gary is the founding partner
of Rosebud Productions, a Medical Marijuana Company applicant under MMPR and
he is also a partner in Whistler Medical Marijuana Corporation, one of only 13
licensed producers under Health Canada MMPR. Gary also holds a medical marijuana
license under the MMAR. Gary’s strengths are in business development and
identifying opportunities for business growth. Gary has a strong skill set in
developing business relationships whether both domestically and internationally.
Gary’s education includes a Bachelor of Business Administration from the University
of Regina with a major in marketing. Through Gary’s experience and education, he
has developed strong analytical skills.
Robert Hall, BEd – Director
 Mr. Hall brings over 10 years’ experience in management in both public and private
companies to Windfire Capital Corp. He is active as a director and officer of multiple
Canadian reporting issuers. Mr. Hall is formally educated with a Bachelor of
Education from the University of British Columbia.
20www.windfirecapital.com
OFFERING SIZE: A maximum of $600,000
Financing – Terms
 Each Unit consists of one Common Share (“Share”) and one-
half (1/2) transferable Warrant (“Warrant”).
 Each Whole Warrant shall entitle the holder to purchase an
additional Common Share for $0.25, and is exercisable for a
period of 24 months from the distribution date.
www.windfirecapital.com
OFFERING: A maximum of 4,000,000 units ( “Unit”), will be offered
through a combined Brokered and non Brokered private placement.
OFFERING PRICE: $0.15 per Unit
21
Share Structure
Share Structure
Issued & Outstanding 25,535,355
Warrants 6,006,000
Options 2,250,000
Fully Diluted 33,791,355
As of July 20, 2014
www.windfirecapital.com 22
Contact Information
www.windfirecapital.com
For further information, please contact:
Clive Massey – President & CEO
(604) 669-2191 O
(604) 644-6794 C
clive@windfirecapital.com
Brian Morrison – CFO & Director
(604) 669-2191 O
(604) 312-6910 C
brian@windfirecapital.com
23
Disclaimer
Ontario
The following statutory rights of action for damages or rescission will only apply to a purchase of securities of the Company in the event that this presentation is deemed to be an offering
memorandum pursuant to securities law applicable in the Province of Ontario. These remedies, or notice with respect thereto, must be exercised, or delivered, as the case may be, by the
purchaser within the time limits prescribed by the applicable provisions of Ontario securities law. Purchasers should refer to such applicable securities legislation for the complete text of
these rights or consult with a legal adviser. Where used in this section, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is
required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made.
Ontario securities law provides that when an offering memorandum is delivered to an investor to whom securities are distributed in reliance upon the "accredited investor" prospectus
exemption provided in Section 2.3 of National Instrument 45-106 (the "Accredited Investor Exemption"), the right of action described below is applicable, unless the prospective
purchaser is: (a) an association governed by the Cooperative Credit Associations Act (Canada) or a central cooperative credit society for which an order has been made under Section
473(1) of that Act; (b) a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services corporation, or
league that, in each case, is authorized by an enactment of Canada or a jurisdiction of Canada to carry on business in Canada or a jurisdiction in Canada; (c) a Schedule III bank, meaning
an authorized foreign bank named in Schedule III of the Bank Act (Canada); (d) the Business Development Bank of Canada incorporated under the Business Development Bank of Canada
Act (Canada); or (e) a subsidiary of any person referred to in paragraphs (a), (b), (c) or (d), if the person owns all of the voting securities of the subsidiary, except the voting securities
required by law to be owned by the directors of the subsidiary.
Where an offering memorandum that contains a misrepresentation is delivered in connection with a trade made in reliance on the Accredited Investor Exemption or certain other
exemptions available under Ontario securities law, a purchaser who purchases a security offered by the offering memorandum during the period of distribution will have, without regard
to whether the purchaser relied on the misrepresentation, a statutory right of action for damages against the issuer and a selling security holder on whose behalf the distribution was
made or, while still the owner of securities against the issuer or selling security holder on whose behalf the distribution was made for rescission. If the purchaser elects to exercise the
right of rescission, the purchaser will have no right of action for damages. The right of action will be exercisable by the purchaser only if the purchaser commences the action, in the case
of any action for rescission, not more than 180 days after the date of the transaction that gave rise to the cause of action and in the case of any action, other than an action for rescission,
before the earlier of: (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action, or (ii) three years after the date of the transaction that gave rise to
the cause of action.
A defendant will not be liable for a misrepresentation if it proves that the purchaser purchased the securities with knowledge of the misrepresentation. In an action for damages, the
defendant shall not be liable for all or any portion of the damages that the defendant proves do not represent the depreciation in value of the securities as a result of the
misrepresentation relied upon. In no case shall the amount recoverable for the misrepresentation that exceeds the price at which the securities were offered.
United States
This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any such offer to sell or solicitation of an
offer to buy the securities described herein or during the presentation will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any
such offering will be made in the United States in reliance upon an exemption from registration under the U.S. Securities Act of 1933, as amended (the "US Securities Act"), for an offer
and sale of securities that does not involve a public offering, and the offer and sale of the securities will be conditioned on the receipt of representations, warranties and agreements of
prospective purchasers to establish that exemption.
Any securities described in this document have not been, and will not be, registered under the US Securities Act and may not be offered or sold in the United States except in transactions
exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.
www.windfirecapital.com 24

More Related Content

What's hot

American International Holdings Deck 2021
American International Holdings Deck 2021American International Holdings Deck 2021
American International Holdings Deck 2021
RedChip Companies, Inc.
 
New health plan identifier & certifucation requirements for self insured plans
New health plan identifier & certifucation requirements for self insured plansNew health plan identifier & certifucation requirements for self insured plans
New health plan identifier & certifucation requirements for self insured plans
Patti Goldfarb, CSA
 
Dplo investor deck april 2015
Dplo investor deck april 2015Dplo investor deck april 2015
Dplo investor deck april 2015
DiplomatIR
 
August Investor Presentation
August Investor Presentation August Investor Presentation
August Investor Presentation
Teranga Gold
 
Can Fite Investor Presentation July 2021
Can Fite Investor Presentation July 2021Can Fite Investor Presentation July 2021
Can Fite Investor Presentation July 2021
RedChip Companies, Inc.
 
3 q14 presentation
3 q14 presentation3 q14 presentation
3 q14 presentation
Valeant_Pharmaceuticals
 
Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017
medreleafinvestor
 
LCA Prospectus V6.0
LCA Prospectus V6.0LCA Prospectus V6.0
LCA Prospectus V6.0
Luis Ramos, MD
 
Epa presentation
Epa presentationEpa presentation
Epa presentation
Arzish Baaquie
 
Medicine Man Tech Presentation
Medicine Man Tech PresentationMedicine Man Tech Presentation
Medicine Man Tech Presentation
RedChip Companies, Inc.
 
Corporate Presentation - July 2013
Corporate Presentation - July 2013Corporate Presentation - July 2013
Corporate Presentation - July 2013
OpexaTherapeutics
 
LTRN Investor Presentation
LTRN Investor PresentationLTRN Investor Presentation
LTRN Investor Presentation
RedChip Companies, Inc.
 
LTRN Investor Presentation - March 2022
LTRN Investor Presentation - March 2022LTRN Investor Presentation - March 2022
LTRN Investor Presentation - March 2022
RedChip Companies, Inc.
 
Stock Market Update
Stock Market UpdateStock Market Update
Stock Market Update
Sarah Cuddy
 
IDFC Sterling Value Fund_One pager
IDFC Sterling Value Fund_One pagerIDFC Sterling Value Fund_One pager
IDFC Sterling Value Fund_One pager
JubiIDFCEquity
 
Draganfly Deck January 2022
Draganfly Deck January 2022Draganfly Deck January 2022
Draganfly Deck January 2022
RedChip Companies, Inc.
 
NEWT Investor Presentation 2022
NEWT Investor Presentation 2022NEWT Investor Presentation 2022
NEWT Investor Presentation 2022
RedChip Companies, Inc.
 
Draganfly Deck March 2022
Draganfly Deck March 2022Draganfly Deck March 2022
Draganfly Deck March 2022
RedChip Companies, Inc.
 

What's hot (18)

American International Holdings Deck 2021
American International Holdings Deck 2021American International Holdings Deck 2021
American International Holdings Deck 2021
 
New health plan identifier & certifucation requirements for self insured plans
New health plan identifier & certifucation requirements for self insured plansNew health plan identifier & certifucation requirements for self insured plans
New health plan identifier & certifucation requirements for self insured plans
 
Dplo investor deck april 2015
Dplo investor deck april 2015Dplo investor deck april 2015
Dplo investor deck april 2015
 
August Investor Presentation
August Investor Presentation August Investor Presentation
August Investor Presentation
 
Can Fite Investor Presentation July 2021
Can Fite Investor Presentation July 2021Can Fite Investor Presentation July 2021
Can Fite Investor Presentation July 2021
 
3 q14 presentation
3 q14 presentation3 q14 presentation
3 q14 presentation
 
Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017
 
LCA Prospectus V6.0
LCA Prospectus V6.0LCA Prospectus V6.0
LCA Prospectus V6.0
 
Epa presentation
Epa presentationEpa presentation
Epa presentation
 
Medicine Man Tech Presentation
Medicine Man Tech PresentationMedicine Man Tech Presentation
Medicine Man Tech Presentation
 
Corporate Presentation - July 2013
Corporate Presentation - July 2013Corporate Presentation - July 2013
Corporate Presentation - July 2013
 
LTRN Investor Presentation
LTRN Investor PresentationLTRN Investor Presentation
LTRN Investor Presentation
 
LTRN Investor Presentation - March 2022
LTRN Investor Presentation - March 2022LTRN Investor Presentation - March 2022
LTRN Investor Presentation - March 2022
 
Stock Market Update
Stock Market UpdateStock Market Update
Stock Market Update
 
IDFC Sterling Value Fund_One pager
IDFC Sterling Value Fund_One pagerIDFC Sterling Value Fund_One pager
IDFC Sterling Value Fund_One pager
 
Draganfly Deck January 2022
Draganfly Deck January 2022Draganfly Deck January 2022
Draganfly Deck January 2022
 
NEWT Investor Presentation 2022
NEWT Investor Presentation 2022NEWT Investor Presentation 2022
NEWT Investor Presentation 2022
 
Draganfly Deck March 2022
Draganfly Deck March 2022Draganfly Deck March 2022
Draganfly Deck March 2022
 

Viewers also liked

2016 Beneplan HR Workshop - Marijuana in the Workplace and Travel Insurance ...
2016 Beneplan HR Workshop - Marijuana in the Workplace  and Travel Insurance ...2016 Beneplan HR Workshop - Marijuana in the Workplace  and Travel Insurance ...
2016 Beneplan HR Workshop - Marijuana in the Workplace and Travel Insurance ...
Beneplan
 
Reasonable suspicion
Reasonable suspicionReasonable suspicion
Reasonable suspicion
Cardinal University
 
Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana
Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana
Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana
Rudner Law
 
Conference Board of Canada Presentation: Medical marijuana in the workplace
Conference Board of Canada Presentation: Medical marijuana in the workplaceConference Board of Canada Presentation: Medical marijuana in the workplace
Conference Board of Canada Presentation: Medical marijuana in the workplace
Rudner Law
 
Hr policy
Hr policyHr policy
Policies for Marijuana Use in the Workplace
Policies for Marijuana Use in the WorkplacePolicies for Marijuana Use in the Workplace
Policies for Marijuana Use in the Workplace
shrm
 

Viewers also liked (6)

2016 Beneplan HR Workshop - Marijuana in the Workplace and Travel Insurance ...
2016 Beneplan HR Workshop - Marijuana in the Workplace  and Travel Insurance ...2016 Beneplan HR Workshop - Marijuana in the Workplace  and Travel Insurance ...
2016 Beneplan HR Workshop - Marijuana in the Workplace and Travel Insurance ...
 
Reasonable suspicion
Reasonable suspicionReasonable suspicion
Reasonable suspicion
 
Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana
Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana
Medavie Blue Cross Benefits3 Conference: Accommodation of Medical Marijuana
 
Conference Board of Canada Presentation: Medical marijuana in the workplace
Conference Board of Canada Presentation: Medical marijuana in the workplaceConference Board of Canada Presentation: Medical marijuana in the workplace
Conference Board of Canada Presentation: Medical marijuana in the workplace
 
Hr policy
Hr policyHr policy
Hr policy
 
Policies for Marijuana Use in the Workplace
Policies for Marijuana Use in the WorkplacePolicies for Marijuana Use in the Workplace
Policies for Marijuana Use in the Workplace
 

Similar to Windfire Capital - Medical Marijuana Firm

Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2
Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2
Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2
Internet Advisory Corp
 
Red Earth Cannabis
Red Earth CannabisRed Earth Cannabis
Red Earth Cannabis
Eric Liboiron
 
Flower One Investor Presentation March
Flower One Investor Presentation MarchFlower One Investor Presentation March
Flower One Investor Presentation March
Flower One Holdings Inc.
 
i1v2e5y5pubs
i1v2e5y5pubs  i1v2e5y5pubs
i1v2e5y5pubs
NarcisaBrandenburg70
 
Dublin day presentation (1)
Dublin day presentation (1)Dublin day presentation (1)
Dublin day presentation (1)
Cardinal_Health
 
Flower One Holdings Inc. Investor Presentation January 2021
Flower One Holdings Inc. Investor Presentation January 2021Flower One Holdings Inc. Investor Presentation January 2021
Flower One Holdings Inc. Investor Presentation January 2021
Flower One Holdings Inc.
 
Flower One Investor Presentation January 2021
Flower One Investor Presentation January 2021Flower One Investor Presentation January 2021
Flower One Investor Presentation January 2021
Flower One Holdings Inc.
 
MMJ BioPharma Labs Introduction
MMJ BioPharma Labs IntroductionMMJ BioPharma Labs Introduction
MMJ BioPharma Labs Introduction
Duane Boise
 
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next Decade
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next DecadeMarijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next Decade
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next Decade
GGS Structures Inc.
 
Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020
Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020
Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020
Flower One Holdings Inc.
 
Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020
Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020
Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020
Flower One Holdings Inc.
 
Tetra Bio-Pharma Investor Presentation
Tetra Bio-Pharma Investor PresentationTetra Bio-Pharma Investor Presentation
Tetra Bio-Pharma Investor Presentation
MomentumPR
 
LOVE - Cannara Biotech - Corporate Presentation
LOVE - Cannara Biotech - Corporate PresentationLOVE - Cannara Biotech - Corporate Presentation
LOVE - Cannara Biotech - Corporate Presentation
MomentumPR
 
ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023
RedChip Companies, Inc.
 
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
Cardinal_Health
 
ZOM Presentation
ZOM PresentationZOM Presentation
ZOM Presentation
RedChip Companies, Inc.
 
CROP Infrastructure - Corporate Presentation
CROP Infrastructure - Corporate PresentationCROP Infrastructure - Corporate Presentation
CROP Infrastructure - Corporate Presentation
MomentumPR
 
Medicine Man Tech Presentation April 2018
Medicine Man Tech Presentation April 2018Medicine Man Tech Presentation April 2018
Medicine Man Tech Presentation April 2018
RedChip Companies, Inc.
 
CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017
CannimedTherapeutics
 
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Sathish Vemula
 

Similar to Windfire Capital - Medical Marijuana Firm (20)

Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2
Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2
Northern spirits-biosciences-group-investor-deck-2.0-jan-16-2019-v2
 
Red Earth Cannabis
Red Earth CannabisRed Earth Cannabis
Red Earth Cannabis
 
Flower One Investor Presentation March
Flower One Investor Presentation MarchFlower One Investor Presentation March
Flower One Investor Presentation March
 
i1v2e5y5pubs
i1v2e5y5pubs  i1v2e5y5pubs
i1v2e5y5pubs
 
Dublin day presentation (1)
Dublin day presentation (1)Dublin day presentation (1)
Dublin day presentation (1)
 
Flower One Holdings Inc. Investor Presentation January 2021
Flower One Holdings Inc. Investor Presentation January 2021Flower One Holdings Inc. Investor Presentation January 2021
Flower One Holdings Inc. Investor Presentation January 2021
 
Flower One Investor Presentation January 2021
Flower One Investor Presentation January 2021Flower One Investor Presentation January 2021
Flower One Investor Presentation January 2021
 
MMJ BioPharma Labs Introduction
MMJ BioPharma Labs IntroductionMMJ BioPharma Labs Introduction
MMJ BioPharma Labs Introduction
 
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next Decade
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next DecadeMarijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next Decade
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next Decade
 
Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020
Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020
Flower One Holdings - Q2 2020 Investor Presentation - September 9, 2020
 
Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020
Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020
Flower One Holdings - Q3 2020 Investor Presentation - November 30, 2020
 
Tetra Bio-Pharma Investor Presentation
Tetra Bio-Pharma Investor PresentationTetra Bio-Pharma Investor Presentation
Tetra Bio-Pharma Investor Presentation
 
LOVE - Cannara Biotech - Corporate Presentation
LOVE - Cannara Biotech - Corporate PresentationLOVE - Cannara Biotech - Corporate Presentation
LOVE - Cannara Biotech - Corporate Presentation
 
ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023
 
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
 
ZOM Presentation
ZOM PresentationZOM Presentation
ZOM Presentation
 
CROP Infrastructure - Corporate Presentation
CROP Infrastructure - Corporate PresentationCROP Infrastructure - Corporate Presentation
CROP Infrastructure - Corporate Presentation
 
Medicine Man Tech Presentation April 2018
Medicine Man Tech Presentation April 2018Medicine Man Tech Presentation April 2018
Medicine Man Tech Presentation April 2018
 
CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017
 
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
 

Recently uploaded

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Gokuldas Hospital
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
KerlynIgnacio
 
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
PVI, PeerView Institute for Medical Education
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
MuhammadMuneer49
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Rahul Sen
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
SIVAVINAYAKPK
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 

Recently uploaded (20)

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
 
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 

Windfire Capital - Medical Marijuana Firm

  • 1. Medical Marijuana Corporate Presentation November 2014 This presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein. The sole purpose of this presentation, in paper or electronic form, is strictly for information.
  • 2. Forward Looking Statement This presentation contains forward-looking statements and "forward-looking information" within the meaning of applicable Canadian securities legislation, including statements relating to business trends, Windfire Capital Corp. expectations with respect to the demand for its services and products, the Windfire Capital Corp.’s intention with respect to its business strategy and competition and changes in the competitive landscape. All statements, other than statements of historical fact, included herein may be forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. This forward looking information reflects Windfire Capital Corp.’s current beliefs and is based on information currently available to Windfire Capital Corp. and on assumptions Windfire Capital Corp. believes are reasonable. These assumptions include, but are not limited to, the size and/or economics of the market, plans and intentions to increase market share, expand geographically and/or further develop product capabilities, the results of strategic initiatives, and the impact of competition. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Windfire Capital Corp. to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the stage of development of Windfire Capital Corp. and its projects, general business, economic, competitive, political and social uncertainties; changes in legislation, the corporate governance environment and regulatory reporting requirements for Windfire Capital Corp. clients, product capability and acceptance, actions from competitors, Windfire Capital Corp.’s ability to generate sufficient cash flow from operations to meet its current and future obligations, and Windfire Capital Corp.’s ability to access external sources of financing if required, and lack of qualified, skilled about and the loss of key individuals. Although Windfire Capital Corp. has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Windfire Capital Corp. does not undertake to update any forward-looking information, except in accordance with applicable securities laws. Also, please review the Ontario and USA disclaimer at end of the presentation. © 2014 Windfire Capital Corp. All rights reserved. Copyright. All materials displayed or otherwise accessible through this Presentation (collectively, "Content") are protected by copyright law, and are owned by Windfire Capital Corp. Corp. (“WIF”) and its licensors, or the party accredited as the provider of the Content. Except as granted in the limited license herein, any use of the Content, including modification, transmission, presentation, distribution, republication, or other exploitation of the Presentation or of its Content, whether in whole or in part, is prohibited without the express prior written consent of WIF. 2www.windfirecapital.com
  • 3. About Windfire Capital Corp. • Windfire Capital Corp. (“Windfire”) is publicly traded company on the TSX Venture Exchange, TSX.V ("WIF"), and the company is led by an experienced management team comprised of public market professionals and skilled operational people from the Medical Marijuana industry. • Windfire has received conditional approval to list on Canadian Securities Exchange (CSE) as a Life Science issuer and subsequently delist from the TSX.V. • Windfire has executed definitive agreement with Rosebud Productions Inc., (“Rosebud”) located in Richmond, British Columbia. Rosebud has submitted an application to Health Canada to become a LP of Medical Marijuana under the new MMPR. • Windfire sees this agreement with Rosebud as being the first step in becoming a multi licensed producer. On that basis, Windfire continues to search for other related opportunities in the Medical Marijuana industry and looks forward to becoming a leading producer of the highest quality Medical Marijuana. 3www.windfirecapital.com
  • 4. About Rosebud Productions Inc.  Rosebud, a private company incorporated under the laws of British Columbia.  Rosebud has an application pending with Health Canada for the newly implemented MMPR license. Once the application is approved Rosebud expects to be producing Medical Marijuana by next spring.  The Rosebud team consists of seasoned industry personnel with experience in all aspects of Medical Marijuana production including cultivation, facility design and construction.  Incoming Windfire board member Gary Quo Vadis and partner Jesse McConnell are the founders and controlling shareholders of Rosebud.  Gary Quo Vadis currently holds a licence under the MMAR regulations. www.windfirecapital.com 4
  • 5. The Opportunity Government of Canada is both exiting the production business and eliminating the practice of allowing nearly 30,000 home growers. Marijuana* for Medical Purposes Regulations legislation from Health Canada has defined a commercial supply chain.  The Canadian Association of Chiefs of Police has been working closely with Health Canada to ensure these regulations address public safety considerations.  Medical marijuana grew from under 500 prescriptions in 2002 to more than 28,000 in 2012 and is expected to reach 40,000 in 2014.  A recent Health Canada survey indicates ~2.0% of Canadians believe they are eligible to use medicinal marijuana, compared to 0.08% of the population currently benefiting from use.  2.0% participation is consistent with other jurisdictions where access requirements have been relaxed (i.e. Colorado). 5www.windfirecapital.com
  • 6.  In June 2013, the Government of Canada published the new Marijuana for Medical Purposes Regulations (“MMPR”) replacing the existing marijuana Medical Access Program (“MMAR”) that was introduced in 2001  In 2001, there were 500 authorized users of medicinal marijuana in Canada, today there are 35,000+ MMPR Regulations MMPR (2013)  Required specialist consultation and prescription including 20-page application form  Licensed commercial producers  Regulated quality control standards  Physical security regulations and enforcement  Detailed record keeping and audit from seed to end product  Ability to purchase directly from Health Canada www.windfirecapital.com 6
  • 7. Investment Highlights  Proven Management  Experienced operational cultivation team  Application submitted to Health Canada  Superior Growth Strategy  Strong growth predicted industry wide. www.windfirecapital.com 7
  • 8. How the MMPR Process Works  Patients obtain a prescription from a medical doctor for medicinal marijuana with a Health Canada prescription number.  To purchase the medicinal marijuana, patients must provide their original prescription to a commercial producer.  Authorized patients then select a commercial producer to fill and ship their prescription.  No advertising is permitted under new MMPR regulations. Patients will select a vendor from Health Canada’s website, medical practitioner or brand awareness.  Prescription are shipped directly from the producer’s facility to the patient using a bonded courier. www.windfirecapital.com 8
  • 9. The Market  The present market is estimated at 37,000 patients.  According to Health Canada, the current licenses translate to about 3.5 million plants.  If each of those 3.5 million plants contributed an average of 56 grams that equates to $1.4 billion at an average price of $7.15. This number does not include the recreational user who buys on the black market.  Health Canada anticipates by 2024 there will be more than 450,000 people using marijuana for medical reasons, creating billions in annual sales.  A majority of people in Canada believe marijuana should be readily available for those who want to use it.  A recent Angus Reid Public Opinion poll has found: – In the online survey of representative national samples, a majority of Canadians (57%) and Americans (54%) support the legalization of marijuana. – Most respondents in each Canadian region back the legalization of cannabis, including 64 per cent of Atlantic Canadians and 60 per cent of British Columbians. www.windfirecapital.com 9
  • 10. Review of Potential Market  The number of prescription users in Canada is expected to grow tenfold over the next ten years.  Health Canada has issued 23 licenses to date.  Estimates indicate 37,000 patients will use an average of 2 grams per day equating to 27,010 kg and will grow to 270,100 kg over the next ten years.  Recently released Liberal Party of Canada research indicates 3 million users in Canada equating to a six billion dollar market place. www.windfirecapital.com 10
  • 11. Financial Projections 11www.windfirecapital.com 2015 2016 2017 2018 2019 Revenue $2,939,650 $7,055,160 $10,317,150 $16,126,080 $26,210,328 Net Income $917,522 $3,653,911 $5,760,732 $9,734,278 $16,767,606 New Equity Investment $3,500,000 $1,500,000 $1,500,00 Cash From Operations $995,424 $3,848,406 $5,995,199 $10,077,907 $17,096,338 Total Assets $4,897,230 $10,160,618 $17,508,278 $27,441,095 $44,382,900 Total Equity $4,850,932 $10,004,843 $17,265,575 $26,999,852 $43,767,458 Earnings per Share (assume 45.5M) $0.02 $0.08 $0.13 $0.21 $0.37 Return on Equity 18.9% 36.5% 33.4% 36.1% 38.3% Return on Revenue 31.2% 51.8% 55.8% 60.4% 64.0% Financials Projections Summary – Year Ending December 31, 2015-2019
  • 12. Revenue & Income Growth 5YR www.windfirecapital.com 12 2015 2016 2017 2018 2019 Revenue $2,939,650 $7,055,160 $10,317,150 $16,126,080 $26,210,328 Net Income $917,522 $3,653,911 $5,760,732 $9,734,278 $16,767,606 Revenue & Income Growth
  • 13. Review of Competition  Industry experts expect high margins as prices initially range from $5-$20 per gram while production costs are expected to be $1-$2 per gram.  Operating expenses will include capital expenditures, production, sales & marketing, and security.  Successful companies will be those that can demonstrate the ability to manufacture, deliver, and scale quickly.  Producers will have to have experienced cultivation and horticulture specialists, careful quality control and security measures, and thorough record keeping procedures to satisfy Health Canada 13www.windfirecapital.com
  • 14. The Acquisition – Rosebud  Pursuant to the terms of the share exchange agreement signed July 15, 2014, the total purchase price, $5 million for Rosebud.  Windfire will make an advance payment of $250,000 dollars to Rosebud on exchange approval.  A 2nd cash payment of $750,000 will be made to Rosebud on conformation that Health Canada has issued a permit to build the cultivation / production facility.  A 3rd cash payment of $1,000,000 dollars will be made to Rosebud on Health Canada granting the MMPR license to operate.  A final payment of $3,000,000 dollars in shares will be paid in two tranches over two years based on performance criteria. www.windfirecapital.com 14
  • 15. Technical Team Cindy Chow, B.Sc. in Food, Nutrition, and Health – Quality Assurance / Safety Manager  Miss Chow has over 8 years’ experience in the food industry specializing in Quality Assurance, Regulatory Affairs, HPLC, Research and Development and Internal Auditing  Solid understanding of GFSI recognized schemes with internal audit experience against BRC and FSSC 22000 standards and ISO 9001:2008 standards  Extensive knowledge of CFIA/FDA regulations and labelling of various RTE products  Experienced in HACCP, GMP, GLP, and Pre-requisite Programs  Outstanding trouble-shooting, problem solving, and time management skills with the ability to work effectively in a team based environment or independently Dean Laidlow – Chief Technical Advisor  Mr. Laidlow has consulted both domestically and internationally in the Medical Marijuana Industry for many years during which time he has developed a vast pool of contacts.  Dean has supervised numerous medical marijuana facilities on a day to day basis resulting in an intimate understanding of all operational aspects of commercial medical marijuana growing facilities. Additionally, he has designed and been instrumental in the construction phase of numerous growing facilities. www.windfirecapital.com 15
  • 16. Technical Team Cont’d. Victor Lam – Head Grower  Mr. Lam as head grower has managed all activities related to growing with Rosebud.  Mr. Lam has knowledge of large scale commercial plant cultivation including nutrient requirements, mediums, light requirements, temperature control, and air flow.  Has experience managing a large-scale warehouse with 100 thousand watt grow lights.  Manages plant scheduling and organization to precisely project all garden needs on a daily, weekly, and monthly basis to keep garden green and expenses low.  Responsible for Cataloging and analyzing each individual strain from clone to flower to harvesting.  Working knowledge in container systems with soil and hydro as well as understanding temperature and humidity manipulation.  Develop and/or maintain grow warehouse protocols and nutrient regiment.  Oversee work force of 10 employees. www.windfirecapital.com 16
  • 17. Facility Build Out  The cost of the facility is estimated to be $500,000. This cost includes, upgrading the fire suppression system, adding 4,200 sq. ft. of mezzanine area, purchasing panel wall system, upgrading the electrical systems and installing a state of the art security system including a vault. www.windfirecapital.com Projects ($000) Costs Vault $50 Mezzanine build out $125 Wall paneling system $90 Fire suppression system $40 Security system $30 Inventory management & POS system $15 Lights, Co2 system, ventilation $150 Total Capital Expenditure $500 17
  • 18. Management & Board Clive Massey – President & Chief Executive Officer and Director  Mr. Massey was previously the President and Chief Executive Officer of Universal Uranium Inc. from 2005 to 2007. From 2005 to 2007, Mr. Massey worked for several successful public companies including Lumina Copper Corp., which was purchased by Teck Cominco Ltd. in 2008. Mr. Massey has held management or investor relations positions with Inca Pacific, Greystar Resources, Marafill Mines, Everett Resources Ltd. and The North Air Group of Companies. Brian Morrison, BComm – Chief Financial Officer and Director  Mr. Morrison received a bachelor of commerce degree from the University of Northern British Columbia in 2004, and completed the Canadian securities course in 2006. From January, 2005, to May, 2008, Mr. Morrison was an account manager with Computershare Investor Services Inc., an international full-service financial services, corporate trust and stock transfer company, and since June, 2008, he has been a self-employed consultant working in the area of public company administration. Mr. Morrison currently serves and has previously served as a director or as chief financial officer of various publicly traded issuers. 18www.windfirecapital.com
  • 19. Management & Board Cont’d. Robert C. Harrison – Director  Mr. Harrison has spent 35 years as an executive in branding, marketing and General Management and after having attained the position of Senior Vice President and General Manager of William Neilson Ltd. Mr. Harrison went on to build several other very successful brands and was responsible for acquiring the licenses and launching both Haagen Dazs and Ben & Jerry's Ice Cream in Canada. Mr. Harrison has consulted for many Fortune 500 companies including Heinz, Nabisco, Nestle and Slim Fast. He has an extensive corporate background in product branding, licensing, manufacturing and the food processing industry. Mr. Harrison is currently President of Global Garden Group of Vancouver, B.C., which is a dairy-free natural food beverage. He was also responsible for engaging and securing the license in Canada for Cadbury and Weight Watchers and in raising in excess of $30 million for plant construction and operational deployment. His extensive back ground includes, numerous debt and equity financings, reverse take overs and the creation of a business strategy that has resulted in business growth in excess of 50% year over year. 19www.windfirecapital.com
  • 20. Management & Board Cont’d. Gary Quo Vadis, BBA – Director  Mr. Quo Vadis has a diverse business background that includes start-up businesses and or buying existing businesses over the last 25 years. Gary is the founding partner of Rosebud Productions, a Medical Marijuana Company applicant under MMPR and he is also a partner in Whistler Medical Marijuana Corporation, one of only 13 licensed producers under Health Canada MMPR. Gary also holds a medical marijuana license under the MMAR. Gary’s strengths are in business development and identifying opportunities for business growth. Gary has a strong skill set in developing business relationships whether both domestically and internationally. Gary’s education includes a Bachelor of Business Administration from the University of Regina with a major in marketing. Through Gary’s experience and education, he has developed strong analytical skills. Robert Hall, BEd – Director  Mr. Hall brings over 10 years’ experience in management in both public and private companies to Windfire Capital Corp. He is active as a director and officer of multiple Canadian reporting issuers. Mr. Hall is formally educated with a Bachelor of Education from the University of British Columbia. 20www.windfirecapital.com
  • 21. OFFERING SIZE: A maximum of $600,000 Financing – Terms  Each Unit consists of one Common Share (“Share”) and one- half (1/2) transferable Warrant (“Warrant”).  Each Whole Warrant shall entitle the holder to purchase an additional Common Share for $0.25, and is exercisable for a period of 24 months from the distribution date. www.windfirecapital.com OFFERING: A maximum of 4,000,000 units ( “Unit”), will be offered through a combined Brokered and non Brokered private placement. OFFERING PRICE: $0.15 per Unit 21
  • 22. Share Structure Share Structure Issued & Outstanding 25,535,355 Warrants 6,006,000 Options 2,250,000 Fully Diluted 33,791,355 As of July 20, 2014 www.windfirecapital.com 22
  • 23. Contact Information www.windfirecapital.com For further information, please contact: Clive Massey – President & CEO (604) 669-2191 O (604) 644-6794 C clive@windfirecapital.com Brian Morrison – CFO & Director (604) 669-2191 O (604) 312-6910 C brian@windfirecapital.com 23
  • 24. Disclaimer Ontario The following statutory rights of action for damages or rescission will only apply to a purchase of securities of the Company in the event that this presentation is deemed to be an offering memorandum pursuant to securities law applicable in the Province of Ontario. These remedies, or notice with respect thereto, must be exercised, or delivered, as the case may be, by the purchaser within the time limits prescribed by the applicable provisions of Ontario securities law. Purchasers should refer to such applicable securities legislation for the complete text of these rights or consult with a legal adviser. Where used in this section, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Ontario securities law provides that when an offering memorandum is delivered to an investor to whom securities are distributed in reliance upon the "accredited investor" prospectus exemption provided in Section 2.3 of National Instrument 45-106 (the "Accredited Investor Exemption"), the right of action described below is applicable, unless the prospective purchaser is: (a) an association governed by the Cooperative Credit Associations Act (Canada) or a central cooperative credit society for which an order has been made under Section 473(1) of that Act; (b) a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services corporation, or league that, in each case, is authorized by an enactment of Canada or a jurisdiction of Canada to carry on business in Canada or a jurisdiction in Canada; (c) a Schedule III bank, meaning an authorized foreign bank named in Schedule III of the Bank Act (Canada); (d) the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada); or (e) a subsidiary of any person referred to in paragraphs (a), (b), (c) or (d), if the person owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by the directors of the subsidiary. Where an offering memorandum that contains a misrepresentation is delivered in connection with a trade made in reliance on the Accredited Investor Exemption or certain other exemptions available under Ontario securities law, a purchaser who purchases a security offered by the offering memorandum during the period of distribution will have, without regard to whether the purchaser relied on the misrepresentation, a statutory right of action for damages against the issuer and a selling security holder on whose behalf the distribution was made or, while still the owner of securities against the issuer or selling security holder on whose behalf the distribution was made for rescission. If the purchaser elects to exercise the right of rescission, the purchaser will have no right of action for damages. The right of action will be exercisable by the purchaser only if the purchaser commences the action, in the case of any action for rescission, not more than 180 days after the date of the transaction that gave rise to the cause of action and in the case of any action, other than an action for rescission, before the earlier of: (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action, or (ii) three years after the date of the transaction that gave rise to the cause of action. A defendant will not be liable for a misrepresentation if it proves that the purchaser purchased the securities with knowledge of the misrepresentation. In an action for damages, the defendant shall not be liable for all or any portion of the damages that the defendant proves do not represent the depreciation in value of the securities as a result of the misrepresentation relied upon. In no case shall the amount recoverable for the misrepresentation that exceeds the price at which the securities were offered. United States This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein or during the presentation will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in the United States in reliance upon an exemption from registration under the U.S. Securities Act of 1933, as amended (the "US Securities Act"), for an offer and sale of securities that does not involve a public offering, and the offer and sale of the securities will be conditioned on the receipt of representations, warranties and agreements of prospective purchasers to establish that exemption. Any securities described in this document have not been, and will not be, registered under the US Securities Act and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws. www.windfirecapital.com 24